• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sanofi, Merck participate in pilot for rapid European health technology assessment

Sanofi, Merck participate in pilot for rapid European health technology assessment

October 18, 2013
CenterWatch Staff

Sanofi Pasteur MSD is the first vaccine company to have successfully participated in a pilot testing a new rapid relative effectiveness assessment of health technologies in Europe.

The Rapid Relative Effectiveness Assessment pilot is being run by a unit within the European Network for Health Technology (EUnetHTA), a network of 47 European health technology assessment organizations working together to develop a methodology for an efficient, collaborative process for assessing the value and effectiveness of new health technologies.

Sanofi Pasteur MSD, a European vaccine company, submitted their new shingles vaccine Zostavax as a candidate for review by the network in April 2013—the first rapid assessment of a pharmaceutical product or vaccine. The assessment was completed in about four months and the outcome now will be shared with all EU member states to help facilitate local assessments.

Andrea Rappagliosi, vice president, market access, health policy and medical affairs for Sanofi Pasteur, said, "Our collaboration with EUnetHTA provides us the opportunity to work with an HTAagencies network who shares our commitment to drive improvements in healthcare systems throughout Europe. Agreeing to run the first Rapid Relative Effectiveness pilot on a vaccine addressing an unmet medical need is another tangible sign of the increasing attention that European authorities give to prevention.”

Zostavax is the first and only vaccine available for the prevention of shingles and its complications such as post-herpetic neuralgia for adults over 50 years. The assessment concluded that Zostavax is effective in reducing the frequency of new shingles cases and its complications and has a good safety profile. The EUnetHTA report was published on Sept. 23on the network's website.  

Sanofi Pasteur MSD is a joint venture between Sanofi Pasteur, the vaccine division of Sanofi, and Merck, known as MSD outside the U.S. and Canada. Sanofi Pasteur MSD is the only company in Europe dedicated exclusively to vaccines and is able to draw upon the research experience of Sanofi Pasteur and Merck to develop innovative new vaccines to improve disease prevention across Europe.  

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing